person · Reporting owner

EcoR1 Panacea Holdings II, LLC

Disclosed activity across 1 company

Tapewire entity: 114007
SEC CIK: 0001842055

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

No relationships currently tracked through insider filings.

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

No balances currently tracked through insider filings.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Panacea Acquisition Corp. II

Report date April 28, 2023 · Filed May 02, 2023

Jointly reported with EcoR1 Capital Fund, L.P., EcoR1 Capital Fund Qualified, L.P., EcoR1 Venture Opportunity Fund, LP, EcoR1 Capital, LLC, Biotech Opportunity GP, LLC, NODELMAN OLEG

Section 16 reporting ended · disclosed 2023-05-02. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Class A ordinary sharesSEC Table I · non-derivative	Direct	0	Reported balance After 2023-04-28 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 1 · 2023-04-28 · Disposition to issuer · Disposed 545,000 · Balance 0 F1: On April 10, 2023, Panacea Acquisition Corp. II (the "Company") announced that it did not consummate an initial business combination by April 9, 2023, the deadline under its Amended and Restated Memorandum and Articles of Association. In connection with the winding up of the Company, the Class A ordinary shares, par value $0.0001 per share, held by the Reporting Persons were surrendered for no consideration on April 28, 2023. F2: The reporting owner, EcoR1 Panacea Holdings II, LLC (the "Sponsor"), in whose name the securities reported herein were held, is managed by its managing members, EcoR1 Capital Fund, L.P., EcoR1 Capital Fund Qualified, L.P. and EcoR1 Venture Opportunity Fund, L.P. The general partner of EcoR1 Capital Fund, L.P. and EcoR1 Capital Fund Qualified, L.P. is EcoR1 Capital, LLC and the general partner of EcoR1 Venture Opportunity Fund, L.P. is Biotech Opportunity GP, LLC (together with EcoR1 Capital, LLC, the "General Partners"). Oleg Nodelman is the manager of each of the General Partners. Each of the Reporting Persons may have been deemed to be a beneficial owner of the shares held by the Sponsor but each (other than the Sponsor) disclaims beneficial ownership of any such shares except to the extent of its respective pecuniary interest therein.

Filing footnotes · ownership attribution and instrument terms

F1: On April 10, 2023, Panacea Acquisition Corp. II (the "Company") announced that it did not consummate an initial business combination by April 9, 2023, the deadline under its Amended and Restated Memorandum and Articles of Association. In connection with the winding up of the Company, the Class A ordinary shares, par value $0.0001 per share, held by the Reporting Persons were surrendered for no consideration on April 28, 2023.

F2: The reporting owner, EcoR1 Panacea Holdings II, LLC (the "Sponsor"), in whose name the securities reported herein were held, is managed by its managing members, EcoR1 Capital Fund, L.P., EcoR1 Capital Fund Qualified, L.P. and EcoR1 Venture Opportunity Fund, L.P. The general partner of EcoR1 Capital Fund, L.P. and EcoR1 Capital Fund Qualified, L.P. is EcoR1 Capital, LLC and the general partner of EcoR1 Venture Opportunity Fund, L.P. is Biotech Opportunity GP, LLC (together with EcoR1 Capital, LLC, the "General Partners"). Oleg Nodelman is the manager of each of the General Partners. Each of the Reporting Persons may have been deemed to be a beneficial owner of the shares held by the Sponsor but each (other than the Sponsor) disclaims beneficial ownership of any such shares except to the extent of its respective pecuniary interest therein.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
April 28, 2023 Filed May 2, 2023 17:15 UTC	Panacea Acquisition Corp. II PANA · Entity 114006	Disposition to issuerClass A ordinary shares	545,000	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-23-026595 · doc4.xml · nonDerivative · entry 1 EcoR1 Panacea Holdings II, LLC · CIK 0001842055 · Director · 10% owner EcoR1 Capital Fund, L.P. · CIK 0001567938 · Director · 10% owner EcoR1 Capital Fund Qualified, L.P. · CIK 0001598292 · Director · 10% owner EcoR1 Venture Opportunity Fund, LP · CIK 0001778011 · Director · 10% owner EcoR1 Capital, LLC · CIK 0001587114 · Director · 10% owner Biotech Opportunity GP, LLC · CIK 0001816370 · Director · 10% owner NODELMAN OLEG · CIK 0001454385 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · kind: On April 10, 2023, Panacea Acquisition Corp. II (the "Company") announced that it did not consummate an initial business combination by April 9, 2023, the deadline under its Amended and Restated Memorandum and Articles of Association. In connection with the winding up of the Company, the Class A ordinary shares, par value $0.0001 per share, held by the Reporting Persons were surrendered for no consideration on April 28, 2023. F1 · price: On April 10, 2023, Panacea Acquisition Corp. II (the "Company") announced that it did not consummate an initial business combination by April 9, 2023, the deadline under its Amended and Restated Memorandum and Articles of Association. In connection with the winding up of the Company, the Class A ordinary shares, par value $0.0001 per share, held by the Reporting Persons were surrendered for no consideration on April 28, 2023. F2 · ownership.direct: The reporting owner, EcoR1 Panacea Holdings II, LLC (the "Sponsor"), in whose name the securities reported herein were held, is managed by its managing members, EcoR1 Capital Fund, L.P., EcoR1 Capital Fund Qualified, L.P. and EcoR1 Venture Opportunity Fund, L.P. The general partner of EcoR1 Capital Fund, L.P. and EcoR1 Capital Fund Qualified, L.P. is EcoR1 Capital, LLC and the general partner of EcoR1 Venture Opportunity Fund, L.P. is Biotech Opportunity GP, LLC (together with EcoR1 Capital, LLC, the "General Partners"). Oleg Nodelman is the manager of each of the General Partners. Each of the Reporting Persons may have been deemed to be a beneficial owner of the shares held by the Sponsor but each (other than the Sponsor) disclaims beneficial ownership of any such shares except to the extent of its respective pecuniary interest therein. Read SEC document
April 09, 2021 Filed Apr 13, 2021 15:10 UTC	Panacea Acquisition Corp. II PANA · Entity 114006	PurchaseClass A ordinary shares	545,000	$10.00	$5,450,000.00	Disclosure SEC source: 0001213900-21-021365 · ownership.xml · nonDerivative · entry 1 EcoR1 Panacea Holdings II, LLC · CIK 0001842055 · Director · 10% owner NODELMAN OLEG · CIK 0001454385 · Director · CEO and Chairman of the Board EcoR1 Capital Fund, L.P. · CIK 0001567938 · Director · 10% owner EcoR1 Capital Fund Qualified, L.P. · CIK 0001598292 · Director · 10% owner EcoR1 Venture Opportunity Fund, LP · CIK 0001778011 · Director · 10% owner EcoR1 Capital, LLC · CIK 0001587114 · Director · 10% owner Biotech Opportunity GP, LLC · CIK 0001816370 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 545,000 F1 · ownership.direct: The reporting owner, EcoR1 Panacea Holdings II, LLC (the "Sponsor"), in whose name the securities reported herein are held, is managed by its managing members, EcoR1 Capital Fund, L.P., EcoR1 Capital Fund Qualified, L.P. and EcoR1 Venture Opportunity Fund, L.P. The general partner of EcoR1 Capital Fund, L.P. and EcoR1 Capital Fund Qualified, L.P. is EcoR1 Capital, LLC and the general partner of EcoR1 Venture Opportunity Fund, L.P. is Biotech Opportunity GP, LLC (together with EcoR1 Capital, LLC, the "General Partners"). Oleg Nodelman is the manager of each of the General Partners. Each of the Reporting Persons may be deemed a beneficial owner of shares held by the Sponsor but each (other than the Sponsor) disclaims beneficial ownership of any such shares except to the extent of its respective pecuniary interest therein. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.